Search clinical trials for: VAY736 Placebo

Total 53611 results

Novartis Pharmaceuticals

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of VAY736 in Rheumatoid Arthritis Patients

Rheumatoid Arthritis

Germany
Novartis Pharmaceuticals

Active, not recruiting

ADCC Mediated B-Cell dEpletion and BAFF-R Blockade (AMBER)

Autoimmune Hepatitis

United States, Belgium, Germany, United Kingdom, Spain, Switzerland, Argentina, Canada, Japan, Czechia
Novartis Pharmaceuticals

Completed

PD of VAY736 in Patients With Primary Sjögren's Syndrome (CVAY736X2201)

Primary Sjögren's Syndrome

Germany
Novartis Pharmaceuticals

Recruiting

Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome (NEPTUNUS-2)

Sjogren Syndrome

United States, Lebanon, India, Spain, Hungary, Germany, Brazil, Israel, Canada, China, Italy, Chile, Colombia, Argentina, Greece, United Kingdom, Australia, Bulgaria, Japan, Mexico, South Africa, Taiwan, France, Romania, Poland, Slovakia, S...
Novartis Pharmaceuticals

Completed

Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)

Primary Sjogren Syndrome

United States, Belgium, Italy, Austria, Israel, France, Germany, Hungary, Netherlands, United Kingdom, Japan, Portugal, Argentina, Spain, Taiwan, Russian Federation, Romania, Chile, Poland
Novartis Pharmaceuticals

Recruiting

Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome (NEPTUNUS-1)

Sjogren Syndrome

United States, Belgium, Austria, Brazil, Mexico, Portugal, Turkey, China, Spain, Chile, Poland, Germany, Guatemala, Korea, Republic of, Czechia, France, Lithuania, Singapore
Novartis Pharmaceuticals

Not yet recruiting

Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). (SIRIUS-SLE LTE)

Systemic Lupus Erythematosus
Novartis Pharmaceuticals

Recruiting

Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) (SIRIUS-SLE 1)

Systemic Lupus Erythematosus

China, Japan, United States, Spain, Thailand, Brazil, Singapore, Turkey, Israel, Hungary, Portugal, Slovakia, Guatemala, Poland, Czechia, Bulgaria, South Africa, Canada
Novartis Pharmaceuticals

Terminated

Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris

Pemphigus Vulgaris

Taiwan, United States, Austria, Bulgaria
Novartis Pharmaceuticals

Recruiting

Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) (SIRIUS-SLE 2)

Systemic Lupus Erythematosus

United States, Germany, France, Taiwan, Italy, Argentina, Korea, Republic of, Mexico, Malaysia, Chile, Colombia, Romania, Australia, India, United Kingdom
Novartis Pharmaceuticals

Terminated

A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis

Relapse Remitting Multiple Sclerosis

United States, Ukraine, Czechia
Novartis Pharmaceuticals

Active, not recruiting

Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients

Systemic Lupus Erythematosus (SLE)

Hungary, Spain, Germany, Israel, Thailand, France, Russian Federation, China, Japan, Taiwan, Korea, Republic of, Poland, Australia, Argentina, Czechia
Novartis Pharmaceuticals

Recruiting

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis (SIRIUS-LN)

Lupus Nephritis

China, United States, Spain, Germany, Korea, Republic of, Italy, Thailand, Hungary, Brazil, Singapore, Taiwan, Argentina, France, Vietnam, Malaysia, Lithuania, Canada, India, Colombia, Romania, United Kingdom, Czechia, Guatemala, Mexico, Eston... and more
Novartis Pharmaceuticals

Not yet recruiting

Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

Rheumatoid Arthritis | Systemic Lupus Erythematosus | Sjögrens Disease
Novartis Pharmaceuticals

Recruiting

A Randomized, Double-blind 2-arm NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome. (NEPTUNUS-Ext)

Sjogrens Syndrome

Spain, Austria, Japan, Poland, Germany, Turkey, Hungary, Israel, Italy, France, Portugal, Taiwan, Australia, Slovakia, United Kingdom, Brazil, Guatemala, Czechia, Bulgaria, United States, Canada, Argentina, Romania
Novartis Pharmaceuticals

Withdrawn

Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's Syndrome

Primary Sjögren's Syndrome
Novartis Pharmaceuticals

Recruiting

A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia (VAYHIA)

Warm Autoimmune Hemolytic Anemia (wAIHA)

China, Japan, Spain, Singapore, France, Germany, Taiwan, United States, Italy, India, Malaysia, Argentina, Hungary, Israel, Australia, Thailand, United Kingdom, Romania
Novartis Pharmaceuticals

Recruiting

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa

Spain, France, United States, Austria, Germany, Hungary, Belgium, Iceland, Netherlands, Denmark, Czechia
Novartis Pharmaceuticals

Recruiting

Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) (VAYHIT1)

Primary Immune Thrombocytopenia (ITP)

China, United States, Spain, Singapore, Austria, Germany, Belgium, Italy, Japan, Czechia, Hong Kong, Hungary, Malaysia, Argentina, Bulgaria, Turkey, Vietnam, Australia, Thailand, Mexico, United Kingdom, France, Romania, Norway, India
Novartis Pharmaceuticals

Recruiting

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids (VAYHIT2)

Primary Immune Thrombocytopenia

United States, China, Germany, Spain, Singapore, Japan, Taiwan, Belgium, Italy, Czechia, Hungary, Malaysia, Korea, Republic of, Turkey, Argentina, Thailand, India, United Kingdom, France, Australia, Romania, Austria, Norway, Netherlands, Philippin...
Novartis Pharmaceuticals

Active, not recruiting

Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

Germany, Jordan
Novartis Pharmaceuticals

Terminated

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or Refractory CLL Patients (VAY736Y)

Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Spain, United States
Novartis Pharmaceuticals

Terminated

Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United States, Germany, Italy, Canada, Ireland, United Kingdom
Bayer

Completed

Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy (CONCUR)

Colorectal Neoplasms

China, Hong Kong, Taiwan, Vietnam, Korea, Republic of
Novartis Pharmaceuticals

Terminated

VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib

Chronic Lymphocytic Leukemia (CLL)

United States
Novartis Pharmaceuticals

Recruiting

A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies

Primary Immune Thrombocytopenia (ITP)

Spain, Italy, France, Germany, China, Korea, Republic of, Czechia, Turkey, Malaysia, United States, Argentina, Australia, United Kingdom, Poland
Bayer

Terminated

Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo-Controlled Phase-III STudy (COAST)

Colorectal Neoplasms

Belgium, France, Spain, China, United States, Canada, Germany, Portugal, Japan, Israel, United Kingdom, Italy, Australia, Brazil
Bayer

Completed

Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma (RESORCE)

Carcinoma, Hepatocellular

France, Spain, China, Switzerland, United States, Singapore, Germany, Russian Federation, Taiwan, Austria, Czechia, United Kingdom, Korea, Republic of, Australia, Hungary, Italy, Netherlands, Japan, Belgium, Brazil, Argentina
Bayer

Completed

Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST) (GRID)

Gastrointestinal Stromal Tumors

Belgium, Canada, Spain, United States, Finland, Korea, Republic of, Austria, United Kingdom, Italy, China, Israel, France, Poland, Germany, Netherlands, Japan, Singapore
Bayer

Completed

Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma

Carcinoma, Hepatocellular

Italy, Spain, Germany, Korea, Republic of
Bayer

No longer available

Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy (CONSIGN)

Colorectal Neoplasms

France, Belgium, Spain, United States, Canada, Switzerland, Germany, Russian Federation, Australia, Austria, Israel, Italy, Mexico, Netherlands, Norway, United Kingdom, Poland, Hungary, Denmark, Portugal, Finland, Sweden, Ireland, Greece and more
Bayer

Completed

Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy

Metastatic Colorectal Cancer

Belgium, Italy, Spain, Canada, Japan, Czech Republic, United States, Australia, France, Hungary, China, Germany, Israel, Netherlands, Turkey, Portugal, Brazil, Switzerland, Argentina
Bayer

Completed

Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy (REGARD)

Colorectal Neoplasms

Turkey
Bayer

Completed

Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment

Neoplasms

Canada, United States
Bayer

Completed

Regorafenib Phase I Study in Mainland Chinese Patients

Oncology

China
Bayer

Completed

Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors

Neoplasms

Hong Kong, Singapore
Bayer

Completed

Phase I Study to Investigate Pharmacokinetics and Safety of BAY73-4506 in Asian (Japanese) Patients With Solid Tumors.

Tumors

Japan
Bayer

Completed

Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI

Colorectal Neoplasms

Germany
Bayer

Completed

Stivarga Regulatory Post-Marketing Surveillance Study in Korea (StivargaPMS)

Colorectal Neoplasms

Korea, Republic of
Bayer

Completed

Regorafenib Post-marketing Surveillance in Japan

Gastrointestinal Stromal Tumors

Japan
Bayer

Completed

Assessment of Physical Activity During Therapy With Regorafenib for Metastatic Colorectal Cancer (REGO-ACT)

Colorectal Neoplasms

Austria
Bayer

Completed

Stivarga Real Life Evidence in Hungary

Colorectal Neoplasms

Hungary
Bayer

Completed

The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib

Pharmacokinetics | Dietary Fats

United States
Bayer

Completed

Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).

Metastatic Colorectal Cancer

India
Bayer

Not yet recruiting

An Observational Study to Learn More About Treatment With Regorafenib in People With Advanced Gastrointestinal Stromal Tumors in the United States

Advanced Gastrointestinal Stromal Tumor

United States
Bayer

Recruiting

A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies

Solid Malignant Tumors

Taiwan, Japan, Korea, Republic of, France, India, Spain
Bayer

Completed

An Observational Study to Learn More About the Long-Term Responses to Treatment With Regorafenib in Patients With Metastatic Colorectal Cancer in the United States (COLONGER)

Metastatic Colorectal Cancer

United States
Bayer

Completed

A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC

Carcinoma, Renal Cell

United States, France, United Kingdom, Finland, Germany, Poland
Bayer

Completed

Regorafenib Post-marketing Surveillance

Colorectal Neoplasms

Japan
Bayer

Completed

Safety and Effectiveness of Regorafenib (Correlate)

Neoplasms

Austria, Czechia, Switzerland, Italy, France, Mexico, Singapore, Luxembourg, Netherlands, Spain, Taiwan, Denmark, Argentina

Search clinical trials for: VAY736 Placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uganda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations